AlloVir, Inc. (ALVR)
ALVR moved a median of +0.31% 30 minutes after news, and +0.36% by the close. How ALVR actually reacts to news — the realized, point-in-time move the market made, measured across 833 labeled events over the last three years with zero look-ahead.
ALVR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.08% | 53% | 687 |
| 30-min | +0.31% | 58% | 707 |
| 60-min | +0.40% | 61% | 712 |
| to close | +0.36% | 55% | 717 |
| Middle 50% of ALVR reactions | -0.80% to +2.01% |
|---|---|
| Median reaction (30-min) | +0.31% |
| Measured reactions | 833 |
Half of all AlloVir, Inc. news events land between -0.80% and +2.01% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ALVR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALVR's baseline. Nothing else.
Recent ALVR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q Kalaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders | Press release | GlobeNewswire | — | — | |
| Form 8-K Kalaris Therapeutics, For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Jul 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Kalaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS Kalaris Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A Kalaris Therapeutics, For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form DEFA14A Kalaris Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form EFFECT Kalaris Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-3 Kalaris Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | — | — | |
| Form 10-K Kalaris Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-8 Kalaris Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Kalaris Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Oct 28 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Kalaris Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS Kalaris Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A Kalaris Therapeutics, For: Aug 12 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form DEFA14A Kalaris Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | — | |
| Form 8-K Kalaris Therapeutics, For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | — | |
| AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | — | — | |
| Form S-8 Kalaris Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | — | — | |
| Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | — | — | |
| Form 10-Q Kalaris Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Kalaris Therapeutics, For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form SEC STAFF LETTER Allovir, Inc. | SEC filing · Form SEC | SEC EDGAR | +4.14% | -5.69% | |
| Form 8-K Allovir, Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +4.14% | -5.69% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALVR section they belong to.
Where else ALVR is measured.
ALVR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AlloVir, Inc.'s median reaction calculated?
Every labeled ALVR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 833 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of ALVR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALVR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.